These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 24909)
61. [Therapy of terminal kidney failure through transplantation]. Dreikorn K; Röhl L Dtsch Med Wochenschr; 1974 Oct; 99(41):2043-6. PubMed ID: 4154187 [No Abstract] [Full Text] [Related]
62. [Bone marrow transplantation in tumor diseases of the blood system]. Thomas ED Ter Arkh; 1988; 60(5):12-23. PubMed ID: 2902699 [No Abstract] [Full Text] [Related]
63. Allogeneic marrow grafting using HL-A matched donor-recipient sibling pairs. Thomas ED; Bryant JI; Buckner CD; Clift RA; Fefer A; Fialkow PJ; Funk DD; Neiman PE; Rudolph RH; Slichter SJ; Storb R Trans Assoc Am Physicians; 1971; 84():248-61. PubMed ID: 4151544 [No Abstract] [Full Text] [Related]
64. Histocompatibility barriers in human marrow transplantation. Feig SA Am J Pediatr Hematol Oncol; 1980; 2(3):273-80. PubMed ID: 7001944 [No Abstract] [Full Text] [Related]
65. Mechanism of graft failure in HLA-matched and HLA-mismatched bone marrow transplant recipients. Bosserman LD; Murray C; Takvorian T; Anderson KC; Freedman AS; Fitzsimmons J; Coral F; Nadler LM; Schlossman SF; Ritz J Bone Marrow Transplant; 1989 May; 4(3):239-45. PubMed ID: 2659109 [TBL] [Abstract][Full Text] [Related]
68. [Organ transplantation. I. Genetics and immunology]. Häyry P Duodecim; 1977; 93(18):1135-51. PubMed ID: 22430 [No Abstract] [Full Text] [Related]
69. Bone-marrow transplantation from an HL-A non-identical but mixed-lymphocyte-culture identical donor. Lancet; 1973 May; 1(7813):1146-50. PubMed ID: 4123539 [No Abstract] [Full Text] [Related]
70. [Clinical aspects of the graft-versus host disease (author's transl)]. Górski A Przegl Lek; 1977; 34(12):861-4. PubMed ID: 24236 [No Abstract] [Full Text] [Related]
71. Immunoblastic sarcoma in donor cells after bone-marrow transplantation. Gossett TC; Gale RP; Fleischman H; Austin GE; Sparkes RS; Taylor CR N Engl J Med; 1979 Apr; 300(16):904-7. PubMed ID: 34100 [No Abstract] [Full Text] [Related]
72. [Selection of donors for allogeneic bone marrow grafts]. Muller JY Rev Fr Transfus Immunohematol; 1982 Feb; 25(1):57-74. PubMed ID: 6461913 [No Abstract] [Full Text] [Related]
73. Severe combined immunodeficiency disease. Characterization of the disease and results of transplantation. Bortin MM; Rimm AA JAMA; 1977 Aug; 238(7):591-600. PubMed ID: 18618 [TBL] [Abstract][Full Text] [Related]
76. Studies on non HL-A cytotoxic and blocking factor in a patient with immunological deficiency successfully reconstituted by bone marrow transplantation. Jeannet M; Rubinstein A; Pelet B Tissue Antigens; 1973; 3(6):411-6. PubMed ID: 4130126 [No Abstract] [Full Text] [Related]
77. Marrow grafts between unrelated dogs homozygous and identical for DLA antigens. Storb R; Weiden PL; Graham TC; Lerner KG; Thomas ED Transplant Proc; 1977 Mar; 9(1):281-3. PubMed ID: 17195 [No Abstract] [Full Text] [Related]
78. Treatment of severe combined immunodeficiency with bone-marrow from an unrelated, mixed-leucocyte-culture-non-reactive donor. Horowitz SD; Bach FH; Groshong T; Hong R; Yunis EJ Lancet; 1975 Sep; 2(7932):431-3. PubMed ID: 51239 [TBL] [Abstract][Full Text] [Related]
79. Is HL-A typing of clinical significance in cadaver renal transplantation? Belzer FO; Perkins HA; Fortmann JL; Kountz SL; Salvatierra O; Cochrum KC; Payne R Lancet; 1974 Apr; 1(7861):774-7. PubMed ID: 4132709 [No Abstract] [Full Text] [Related]